Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Eulji University Industry Academy Cooperation Foundation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner, Amelia Nicole Dickens, who is the busiest examiner with 1 pending action. The matter is within a distinct art unit, concentrating the current prosecution risk and opportunity with a single examiner.
For the practitioner, the presence of 1 pending action, a distinct examiner, and a distinct art unit means that the prosecution strategy is highly streamlined. There is no need to coordinate between different technical groups or examiner styles. Instead, the focus is entirely on Amelia Nicole Dickens and the specific biotechnology standards of the art unit where the case resides.
The outcome of this 1 pending office action will define the company's current success at the USPTO. The legal team should prioritize a detailed analysis of the examiner's previous actions to anticipate her concerns. By focusing on the specific requirements of this single art unit, the practitioner can provide a more effective and targeted response to the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668477 | Novel anti-cancer vaccine composition and a method of vaccination using the same | DICKENS, AMELIA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18668477 | Novel anti-cancer vaccine composition and a method of vaccination using the same | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18668477 | Novel anti-cancer vaccine composition and a method of vaccination using the same | DICKENS, AMELIA NICOLE | 1645 | §102§103§112 | Non-Final OA | — | Pending | May 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEulji University Industry Academy Cooperation Foundation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amelia Nicole Dickens has the most, with 1 of Eulji University Industry Academy Cooperation Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
